Investment Analysts’ Weekly Ratings Updates for Grifols (GRFS)

Grifols (NASDAQ: GRFS) has recently received a number of price target changes and ratings updates:

• 5/18/2026 – Grifols was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/10/2026 – Grifols was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/8/2026 – Grifols was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/8/2026 – Grifols was downgraded by Zacks Research from “hold” to “strong sell”.
• 5/2/2026 – Grifols was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/27/2026 – Grifols was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.